FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor
Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful
FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor
Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful
Use the share button in your browser
to share the page with your friends